Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd-MVA Vaccination With or Without Cyclophosphamide in Localised Prostate Cancer
NCT02390063Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jun 2015
- Primary completion
- May 2018
- Modality
- Prophylactic Vaccines, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ChAdOx1-MVA 5T4 vaccine and MVA-5T4 in prostate cancer (PCa) (8 arms), sponsored by University of Oxford. Primary endpoint: Vaccine safety and immunogenicity at 52 weeks. Started Jun 2015; status: completed.
02
Drugs
ChAdOx1-MVA 5T4 vaccineMVA-5T4
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02390063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390063.